Bayer will acquire the agricultural company for $66 billion in an all cash transaction.
On Sept. 14, 2016, Bayer and Monsanto signed a long anticipated merger agreement, under which Bayer will acquire the agricultural company for $128 per share, approximately $66 billion, in an all cash transaction. Bayer first proposed the merger in May 2016.
Some of Bayer’s shareholders have been critical of the move, saying the company “risks overpaying and neglecting the company’s pharmaceutical business,” Reuters reports. According to Reuters, the merger will have to be approved by multiple regulators, and the companies will have to file in approximately 30 jurisdictions. The merger is expected to close at the end of 2017.
The combined agriculture business will have its global Seeds & Traits and North American commercial headquarters in St. Louis, Missouri, its global Crop Protection and overall Crop Science headquarters in Monheim, Germany, and an important presence in Durham, North Carolina. The Digital Farming activities for the combined business will be based in San Francisco, California.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.